Switch theme
Sign up to access all valuation multiples
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
2007
181
LTM Revenue $180M
Last FY EBITDA -$13.7M
$878M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Akebia Therapeutics has a last 12-month revenue (LTM) of $180M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Akebia Therapeutics achieved revenue of $160M and an EBITDA of -$13.7M.
Akebia Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Akebia Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $180M | XXX | $160M | XXX | XXX | XXX |
| Gross Profit | $138M | XXX | $97.0M | XXX | XXX | XXX |
| Gross Margin | 77% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$13.7M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -9% | XXX | XXX | XXX |
| EBIT | -$19.3M | XXX | -$50.4M | XXX | XXX | XXX |
| EBIT Margin | -11% | XXX | -31% | XXX | XXX | XXX |
| Net Profit | -$42.9M | XXX | -$69.4M | XXX | XXX | XXX |
| Net Margin | -24% | XXX | -43% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Akebia Therapeutics's stock price is $4.
Akebia Therapeutics has current market cap of $938M, and EV of $878M.
See Akebia Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $878M | $938M | XXX | XXX | XXX | XXX | $-0.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Akebia Therapeutics has market cap of $938M and EV of $878M.
Akebia Therapeutics's trades at 5.5x EV/Revenue multiple, and -64.0x EV/EBITDA.
Equity research analysts estimate Akebia Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Akebia Therapeutics has a P/E ratio of -21.9x.
See valuation multiples for Akebia Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $938M | XXX | $938M | XXX | XXX | XXX |
| EV (current) | $878M | XXX | $878M | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | 5.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -64.0x | XXX | XXX | XXX |
| EV/EBIT | -45.4x | XXX | -17.4x | XXX | XXX | XXX |
| EV/Gross Profit | 6.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -21.9x | XXX | -13.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -21.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAkebia Therapeutics's last 12 month revenue growth is 35%
Akebia Therapeutics's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.8M for the same period.
Akebia Therapeutics's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Akebia Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Akebia Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 35% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -9% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 31% | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 92% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Akebia Therapeutics acquired XXX companies to date.
Last acquisition by Akebia Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Akebia Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Akebia Therapeutics founded? | Akebia Therapeutics was founded in 2007. |
| Where is Akebia Therapeutics headquartered? | Akebia Therapeutics is headquartered in United States of America. |
| How many employees does Akebia Therapeutics have? | As of today, Akebia Therapeutics has 181 employees. |
| Who is the CEO of Akebia Therapeutics? | Akebia Therapeutics's CEO is Mr. John P. Butler. |
| Is Akebia Therapeutics publicy listed? | Yes, Akebia Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Akebia Therapeutics? | Akebia Therapeutics trades under AKBA ticker. |
| When did Akebia Therapeutics go public? | Akebia Therapeutics went public in 2014. |
| Who are competitors of Akebia Therapeutics? | Similar companies to Akebia Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Akebia Therapeutics? | Akebia Therapeutics's current market cap is $938M |
| What is the current revenue of Akebia Therapeutics? | Akebia Therapeutics's last 12 months revenue is $180M. |
| What is the current revenue growth of Akebia Therapeutics? | Akebia Therapeutics revenue growth (NTM/LTM) is 35%. |
| What is the current EV/Revenue multiple of Akebia Therapeutics? | Current revenue multiple of Akebia Therapeutics is 4.9x. |
| Is Akebia Therapeutics profitable? | Yes, Akebia Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
